Corient IA’s ArriVent BioPharma AVBP Stock Holding History

Corient IA’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,500	Closed	-$618K	–	238
2025 Q3	$618K	Buy	+33,500	New	+$658K	0.46%	63

Other funds holding AVBP

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Corient IA's AVBP Position: Q4 2025 in Review

Corient IA sold out of ArriVent BioPharma (AVBP) in Q4 2025, closing a stake of 33,500 shares — an estimated $618K sold.

Corient IA first reported a position in AVBP in Q3 2025 and held it in 1 quarter. The position peaked at $618K in Q3 2025. 121 funds tracked by Wall St. Rank hold AVBP as of Q4 2025.

Corient IA reported no remaining ArriVent BioPharma position as of Q4 2025 after selling out during the quarter.
Corient IA sold 33,500 ArriVent BioPharma shares in Q4 2025, an estimated $618K.
Corient IA first reported a position in ArriVent BioPharma in Q3 2025 and held it in 1 quarter.
Corient IA's ArriVent BioPharma position peaked at $618K in Q3 2025.
121 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2025.

Based on Corient IA's 13F filing for Q4 2025, filed 13 Feb 2026.